Anti-VEGF-refractory Exudative Age-related Macular Degeneration: Differential Response According to Features on Optical Coherence Tomography
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: To describe optical coherence tomography (OCT) characteristics of neovascular age-related maculardegeneration (AMD) patients refractory to intravitreal anti-vascular endothelial growth factor (VEGF) injections(ranibizumab, bevacizumab) and their responses to alternative anti-VEGF agents or photodynamic therapy(PDT). Methods: A retrospective review of 267 neovascular AMD patients treated with intravitreal anti-VEGF injections. Results: Twenty patients (7.5%) were refractory to anti-VEGF injections (stationary or increased retinal exudationdespite three or more monthly injections). They were grouped into either the extensive intraretinal fluidgroup (IRF group, 9 patients) or the subretinal fluid only group (SRF group, 11 patients) according to OCTfindings. In the IRF group, response rates to subsequent treatment were 0% (0 / 7) for bevacizumab, 50% (3/ 6) for ranibizumab and 50% (3 / 6) for PDT ± anti-VEGF. Three out of four bevacizumab-refractory patientsshowed response to ranibizumab as a secondary treatment. In the SRF group, response rates were lowerwith 0% (0 / 7) for bevacizumab, 22.2% (2 / 9) for ranibizumab and 28.6% (2 / 7) for PDT ± anti-VEGF. One outof four bevacizumab-refractory patients responded to ranibizumab. The visual outcome was worse in the IRFgroup (median 20 / 1,000) than in the SRF group (median 20 / 100). Conclusions: In anti-VEGF-refractory neovascular AMD, patients with extensive IRF refractory to bevacizumabcan be responsive to ranibizumab while patients with SRF may be refractory to both, suggesting a differentpathophysiology and intraocular pharmacokinetics.
Abstract
Purpose: To describe optical coherence tomography (OCT) characteristics of neovascular age-related maculardegeneration (AMD) patients refractory to intravitreal anti-vascular endothelial growth factor (VEGF) injections(ranibizumab, bevacizumab) and their responses to alternative anti-VEGF agents or photodynamic therapy(PDT). Methods: A retrospective review of 267 neovascular AMD patients treated with intravitreal anti-VEGF injections. Results: Twenty patients (7.5%) were refractory to anti-VEGF injections (stationary or increased retinal exudationdespite three or more monthly injections). They were grouped into either the extensive intraretinal fluidgroup (IRF group, 9 patients) or the subretinal fluid only group (SRF group, 11 patients) according to OCTfindings. In the IRF group, response rates to subsequent treatment were 0% (0 / 7) for bevacizumab, 50% (3/ 6) for ranibizumab and 50% (3 / 6) for PDT ± anti-VEGF. Three out of four bevacizumab-refractory patientsshowed response to ranibizumab as a secondary treatment. In the SRF group, response rates were lowerwith 0% (0 / 7) for bevacizumab, 22.2% (2 / 9) for ranibizumab and 28.6% (2 / 7) for PDT ± anti-VEGF. One outof four bevacizumab-refractory patients responded to ranibizumab. The visual outcome was worse in the IRFgroup (median 20 / 1,000) than in the SRF group (median 20 / 100). Conclusions: In anti-VEGF-refractory neovascular AMD, patients with extensive IRF refractory to bevacizumabcan be responsive to ranibizumab while patients with SRF may be refractory to both, suggesting a differentpathophysiology and intraocular pharmacokinetics.
참고문헌 (23)
- Rosenfeld PJ, "Ranibizumab for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1419~1431 (2006)
- Brown DM, "Ranibizumab versus verteporfin for neovascular age-related macular degeneration", N Engl J Med, 355, pp.1432~1444 (2006)
- Abraham-Marin ML, "Intravitreal bevacizumab therapy for neovascular age-related macular degeneration : a pilot study", Graefes Arch Clin Exp Ophthalmol, 245, pp.651~655 (2007)
- Avery RL, "Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration", Ophthalmology, 113, pp.363~372 (2006)
- Costa RA, "Intravitreal bevacizumab for choroidal neovascularization caused by AMD(IBeNA Study) : results of a phase 1 dose-escalation study", Invest Ophthalmol Vis Sci, 47, pp.4569~4578 (2006)
- Fong DS, "Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study", Ophthalmology, 117, pp.298~302 (2010)
- Rich RM, "Short-term safety and efficacy of intravitreal bevacizumab(Avastin)for neovascular age-related macular degeneration", Retina, 26, pp.495~511 (2006)
- Fung AE, "An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration", Am J Ophthalmol, 143, pp.566~583 (2007)
- Brown DM, "Anti-VEGF agents in the treatment of neovascular age-related macular degeneration : applying clinical trial results to the treatment of everyday patients", Am J Ophthalmol, 144, pp.627~637 (2007)
- Cho M, "Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy", Am J Ophthalmol, 148, pp.2009~2148 (2009)
- Mojana F, "The role of abnormal vitreomacular adhesion in age-related macular degeneration : spectral optical coherence tomography and surgical results", Am J Ophthalmol, 146, pp.218~227 (2008)
- Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group, "Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin : one-year results of 2 randomized clinical trials--TAP report", Arch Ophthalmol, 117, pp.1329~1345 (1999)
- Lux A, "Non-responders to bevacizumab(Avastin)therapy of choroidal neovascular lesions", Br J Ophthalmol, 91, pp.1318~1322 (2007)
- CATT Research Group, "Ranibizumab and bevacizumab for neovascular age-related macular degeneration", N Engl J Med, 364, pp.1897~1908 (2011)
- Stangos AN, "Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab", Am J Ophthalmol, 150, pp.666~673 (2010)
- Gaudreault J, "Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits", Retina, 27, pp.1260~1266 (2007)
- Kofoed-Enevoldsen A, "Evidence of impaired glomerular charge selectivity in nondiabetic subjects with microalbuminuria : relevance to cardiovascular disease", Arterioscler Thromb Vasc Biol, 16, pp.450~454 (1996)
- Nishihara H, "Studies on the ultrastructure of the inner limiting membrane of the retina : distribution of anionic sites in the inner limiting membrane of the retina", Nihon Ganka Gakkai Zasshi, 95, pp.951~958 (1991)
- Bunt-Milam AH, "Zonulae adherentes pore size in the external limiting membrane of the rabbit retina", Invest Ophthalmol Vis Sci, 26, pp.1377~1380 (1985)
- Kim H, "FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye", Mol Vis, 15, pp.2803~2812 (2009)
- Heiduschka P, "Penetration of bevacizumab through the retina after intravitreal injection in the monkey", Invest Ophthalmol Vis Sci, 48, pp.2814~2823 (2007)
- Shahar J, "Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab(Avastin)", Retina, 26, pp.262~269 (2006)
- Brasil OF, "Predictive factors for short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema : an optical coherence tomography study", Br J Ophthalmol, 91, pp.761~765 (2007)